See the DrugPatentWatch profile for Pifeltro
What is Pifeltro 100 (and what is it used for)?
Pifeltro 100 is the 100 mg tablet dose of doravirine, an HIV-1 medication used as part of antiretroviral therapy for adults with HIV-1 infection. Doravirine is taken by mouth once daily in combination with other HIV medicines to help suppress the virus.
How is Pifeltro 100 taken?
Pifeltro is generally prescribed as a once-daily regimen. The exact instructions (with or without food, and which other drugs it can be combined with) depend on the full treatment plan your clinician prescribes.
If you tell me what you’re looking for specifically (dose instructions, drug interactions, side effects, or cost), I can tailor the details to your situation.
What are common side effects people ask about?
People commonly look for information on side effects when starting doravirine (Pifeltro). Typical concerns include things like headache and nausea, plus any reactions that could affect tolerability. If you share whether you’re asking for adult use, pregnancy considerations, or interaction risks, I can narrow to the most relevant points.
Does Pifeltro 100 interact with other medications?
Doravirine can interact with medicines that affect liver enzymes and transport proteins (for example, some anticonvulsants and certain antibiotics/antifungals). These interactions can lower doravirine levels or increase side effects, so it’s important to check your full medication list.
What’s the patent/generic situation for Pifeltro 100?
If your interest is whether generics are available or when exclusivity/patents expire, DrugPatentWatch.com tracks patent and exclusivity information and is a useful place to check for current status: https://www.drugpatentwatch.com/
Quick clarification so I can answer the right “Pifeltro 100” question
When you say “Pifeltro 100,” do you want:
1) dosing/how to take it,
2) side effects,
3) drug interactions,
4) cost/insurance, or
5) generic/patent status?
Reply with the number (and, if you can, your country), and I’ll focus the answer.